Conventional antipsychotics reduce rehospitalisation rate in schizophrenia

2002 ◽  
Vol 375 (1) ◽  
pp. 7-7
Keyword(s):  
Conventional Antipsychotics ◽  
Rehospitalisation Rate

Increased rehospitalisation rate and cardiovascular morbidity in inpatients with hyperthyroidism - a matched case-control study

2015 ◽  
Author(s):  
Barbara Torlinska ◽  
James Hodson ◽  
Jayne Franklyn ◽  
Jamie Coleman ◽  
Kristien Boelaert
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Cardiovascular Morbidity ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study ◽  
Rehospitalisation Rate

The treatment of mixed states and the risk of switching to depression

2005 ◽  
Vol 20 (2) ◽  
pp. 96-100 ◽  
Author(s):  
Eduard Vieta
Keyword(s):  
Clinical Trials ◽  
Depressive Symptoms ◽  
Mixed State ◽  
Atypical Antipsychotics ◽  
Randomized Clinical Trials ◽  
Mixed States ◽  
Conventional Antipsychotics

AbstractThere are few controlled studies evaluating the treatment of bipolar mixed states. Evidence suggests that mixed states may be more responsive to some anticonvulsants than to lithium. Olanzapine alone or in combination with divalproate or lithium has been adequately evaluated in randomized clinical trials involving mixed-state patients, whereas risperidone and quetiapine have not. There is also some evidence demonstrating the efficacy of ziprasidone and aripiprazole. The risk of switching to depression is high in mixed states. Conventional antipsychotics, such as haloperidol, may be less efficacious at protecting against a switch to depression than atypical antipsychotics, divalproate or lithium. When choosing drugs for the treatment of mania, and especially for the treatment of mixed states, their efficacy against manic and depressive symptoms, and their safety in terms of the risk of switching to depression should be taken into account.

Neither Atypical Nor Conventional Antipsychotics Increase Mortality or Hospital Admissions Among Elderly Patients With Dementia: A Two-Year Prospective Study

2007 ◽  
Vol 15 (5) ◽  
pp. 416-424 ◽  
Author(s):  
Minna M. Raivio ◽  
Jouko V. Laurila ◽  
Timo E. Strandberg ◽  
Reijo S. Tilvis ◽  
Kaisu H. Pitkälä
Keyword(s):  
Elderly Patients ◽  
Prospective Study ◽  
Hospital Admissions ◽  
Conventional Antipsychotics

Effects of atypical and conventional antipsychotics on cognition in schizophrenia

2016 ◽  
Vol 26 ◽  
pp. S347-S348
Author(s):  
A. Arous ◽  
W. Chebbi ◽  
J. Mrizak ◽  
H. Ben Ammar ◽  
Z. El Hechmi
Keyword(s):  
Conventional Antipsychotics

Leptin Concentrations Are Increased in Subjects Treated With Clozapine or Conventional Antipsychotics

2001 ◽  
Vol 62 (11) ◽  
pp. 843-848 ◽  
Author(s):  
Staffan Hagg ◽  
Stefan Soderberg ◽  
Bo Ahren ◽  
Tommy Olsson ◽  
Tom Mjorndal
Keyword(s):  
Conventional Antipsychotics

The Science of Antipsychotics: Mechanistic Insight

CNS Spectrums ◽  
2003 ◽  
Vol 8 (S2) ◽  
pp. 5-9 ◽  
Author(s):  
Carol A. Tamminga
Keyword(s):  
Side Effects ◽  
Tardive Dyskinesia ◽  
Side Effect ◽  
Negative Symptoms ◽  
New Drugs ◽  
Receptor Subtypes ◽  
Side Effect Profile ◽  
Cognitive Symptoms ◽  
Conventional Antipsychotics ◽  
New Antipsychotics

ABSTRACTWith the introduction of conventional antipsychotics in the 1950s, clinicians began to expect effective treatment of positive symptoms of schizophrenia. However, these drugs do not resolve negative and cognitive symptoms of schizophrenia and are also associated with serious side effects, including extrapyramidal side effects (EPS) and tardive dyskinesia. In 1989, clozapine was introduced and labeled the first new antipsychotic owing to its improved efficacy and side-effect profile. Clozapine proved effective in alleviating many of the positive, negative, and cognitive symptoms of schizophrenia, without causing inevitable EPS or tardive dyskinesia. Over the past decade, a number of different new antipsychotics have been developed. These drugs have an affinity for multiple dopamine-receptor subtypes as well as serotonin, norepinephrine, and glutamate receptors, allowing for better treatment outcomes. The antagonism of the 5-HT2A receptor may be responsible for improvement in negative symptoms and decrease in EPS. In addition to providing enhanced efficacy, the affinity of the new drugs for multiple receptors introduces new side effects not seen with the conventional agents, including weight gain. Each new antipsychotic has a unique receptor-binding profile that corresponds to its pharmacologic and side-effect profile. Understanding the differences in mechanisms of action of new antipsychotics will allow physicians to better choose treatment that meets the needs of each individual patient.

scholarly journals PMH22 CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIA

2004 ◽  
Vol 7 (3) ◽  
pp. 270
Author(s):  
L Davies ◽  
S Lewis ◽  
K Hay Hurst
Keyword(s):  
Cost Effective ◽  
Treatment Resistant ◽  
Conventional Antipsychotics

Prescribing Conventional Antipsychotics at Two Veterans Administration Hospitals: Are There Geographical Differences?

CNS Spectrums ◽  
2001 ◽  
Vol 6 (11) ◽  
pp. 894-896
Author(s):  
Prakash S. Masand ◽  
Monica Arora ◽  
Thomas L. Schwartz ◽  
Anil Sharma ◽  
Xiaohong Wang ◽  
...  
Keyword(s):  
New York ◽  
Medical Records ◽  
Alternative Therapies ◽  
Veterans Administration ◽  
Prescribing Practices ◽  
Geographical Differences ◽  
Conventional Antipsychotics ◽  
Geographic Differences

AbstractThe medical records of 110 patients receiving conventional antipsychotics at two geographically distinct Veterans Administration hospitals (Syracuse, New York and Omaha, Nebraska) were reviewed. The most common reasons for continuation of conventional antipsychotics were good response and patient or physician choice. Frequently, physicians did not discuss the reasons for continuing conventional antipsychotics or the availability of alternative therapies with their patients. Geographic differences in physicians' prescribing practices of conventional antipsychotics were apparent.

Sign in / Sign up

Export Citation Format

Share Document